Webinar Recorded on February 11, 2025                           Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Join us for an engaging webinar exploring key considerations in the management and diagnosis of idiopathic hypersomnia (IH). Affecting an estimated 20% of Americans, excessive daytime sleepiness (EDS) results in a substantially elevated risk of motor vehicle and work-related incidents, and individuals suffering from EDS have generally poorer overall health and higher health care resource utilization than comparable adults. Although the etiology of EDS may be multifactorial, central disorders of hypersomnolence—namely, narcolepsy and idiopathic hypersomnia (IH)—represent a direct underlying cause. IH is similar in presentation to narcolepsy, but diagnostic criteria are less definitive. As a result, IH can be difficult to distinguish from narcolepsy.

This session will feature a clinical key opinion leader and payer participants from the roundtable convened by AMCP in November 2024. The presenters will delve into the challenges of distinguishing IH from other sleep disorders, highlight advancements in diagnostic tools, and discuss evolving treatment strategies. Attendees will gain valuable insights into the broader impacts of IH on health outcomes and healthcare systems, with perspectives from clinical and payer experts.

Learning Objectives

• Characterize the impact of EDS and sleep inertia on quality of life in patients with IH.
• Share payer insights on perceived prevalence and disease burden of IH in the United States.
• Review the potential role of AI to facilitate more timely screening and diagnosis of IH.
• Explore the treatment modalities for IH, providing payer insights into coverage policies, utilization management, and the value of emerging therapies.
• Interpret the clinical relevance of sodium intake and its potential impact for patients with specific cardiovascular risk factors.
• Describe the clinical and economic impact of cardiovascular comorbidities in IH.